IVYSPRING INTERNATIONAL PUBLISHER

Journal of Cancer

2023; 14(18): 3567. doi: 10.7150/jca.92106

Erratum

Efficacy of Shikonin against Esophageal Cancer Cells and its possible mechanisms *in vitro* and *in vivo*: Erratum

Jian-Cai Tang[1]✉, Jia Zhao[2], Feng Long[3], Jian-ye Chen[1], Bo Mu[1], Zhen Jiang[1], Yonggan Ren[1], Jian Yang[4]

1. Department of Biochemistry;
2. School of Pharmacy;
3. Department of Pharmacy, Nan Chong Central Hospital;
4. Pathogenic Biology and Immunology Experiment Teaching Center, North of Si Chuan Medical University, China.

*Jian-Cai Tang and Jia Zhao contributed equally to this work.

✉ Corresponding author: Jian-Cai Tang, PhD; North of Si Chuan Medical College, Fu jiang Road 234, Shun Qing District, Nan Chong, Sichuan province, China Post code: 637000; E-mail: tangjiancai@nsmc.edu.cn

Published: 2023.11.28

Corrected article: *J Cancer* 2018; 9(1): 32-40. doi: 10.7150/jca.21224.

In the original version of our article, there was two errors in Fig. 4A. Specifically, the representative images of PI3K and AKT of ECA109 cells in Figure 4A are incorrect. The correct image is provided below. This correction will not affect the results and conclusions. The authors apologize for any inconvenience this may have caused.



Figure 4A: Shikonin inhibited EGFR/PI3K/AKT signal pathway. Ec109 and EC9706 cells were treated with shikonin(0,2,4μg/ml) for 24h and the total protein were extracted, then the expression of EGFR, PI3K, AKT, p-AKT, mTOR, PKM2 and HIF1α were examined by Western blot. The results showed that shikonin decreased the expression of EGFR, PI3K, AKT, p-AKT, mTOR, PKM2 and HIF1α.